FGFR1 and obesity due to melanocortin 4 receptor deficiency: Thus, BAT has gained attention as a novel target for treating obesity and Type 2 diabetes due to its “fat-burning” properties (33), mediated by FGF21-FGFR1 signaling (34, 35).